GlobeNewsWire
16 Nov 2026, 08:28 UTC · 17h ago
Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
Impact · against what's priced in
ACRS is facing a significant valuation hit following the failure of the bosakitug Phase 2 trial in atopic dermatitis. The company's shift in priority toward its oral kinase inhibitors and ATI-052 suggests a loss of a primary near-term growth catalyst.
- ACRS−0.80
No priced-in read yet





